Physician profile
Dilipkumar Joshi
NPI 1669565537
$6,309.64
in general payments reported to CMS, 2019-2025
30 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $623 · 2021: $1,064 · 2022: $1,083 · 2023: $731 · 2024: $1,050 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $752.16 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $667.83 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $586.77 | 2020-2025 | Caplyta |
| Lundbeck LLC | $555.50 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $475.21 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $433.70 | 2019-2025 | Invega, Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $404.28 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $342.04 | 2019-2025 | Trintellix |
| Alkermes, INC. | $326.12 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $211.03 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $209.35 | 2021-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $208.57 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $172.79 | 2019-2020 | |
| Eisai INC. | $158.94 | 2020-2022 | |
| Axsome Therapeutics, INC. | $135.34 | 2022-2025 | Auvelity, Sunosi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $123.10 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.27 | 2022-2024 | Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $70.78 | 2021-2022 | |
| Indivior INC. | $61.57 | 2024-2025 | Sublocade, Perseris |
| Adlon Therapeutics L.P. | $52.01 | 2021 | |
| Almatica Pharma LLC | $40.18 | 2023-2025 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $38.87 | 2023-2024 | Quviviq |
| Tris Pharma INC | $33.47 | 2023-2024 | Dyanavel Xr |
| Janssen Biotech, INC. | $31.67 | 2023 | |
| Braeburn INC. | $31.14 | 2025 | Brixadi |
| Shire North American Group INC | $28.42 | 2019 | |
| Neuronetics, INC. | $24.33 | 2019 | |
| Corium, LLC | $16.98 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilipkumar Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.